129 related articles for article (PubMed ID: 25042396)
1. Substance use disorder and its effects on outcomes in men with advanced-stage prostate cancer.
Chhatre S; Metzger DS; Malkowicz SB; Woody G; Jayadevappa R
Cancer; 2014 Nov; 120(21):3338-45. PubMed ID: 25042396
[TBL] [Abstract][Full Text] [Related]
2. Association between age, substance use, and outcomes in Medicare enrollees with prostate cancer.
Jayadevappa R; Chhatre S
J Geriatr Oncol; 2016 Nov; 7(6):444-452. PubMed ID: 27394148
[TBL] [Abstract][Full Text] [Related]
3. The burden of depression in prostate cancer.
Jayadevappa R; Malkowicz SB; Chhatre S; Johnson JC; Gallo JJ
Psychooncology; 2012 Dec; 21(12):1338-45. PubMed ID: 21837637
[TBL] [Abstract][Full Text] [Related]
4. Variation in quality of care among older men with localized prostate cancer.
Jayadevappa R; Chhatre S; Johnson JC; Malkowicz SB
Cancer; 2011 Jun; 117(11):2520-9. PubMed ID: 24048800
[TBL] [Abstract][Full Text] [Related]
5. Continuity of care and advanced prostate cancer.
Jayadevappa R; Guzzo T; Vapiwala N; Malkowicz SB; Gallo JJ; Chhatre S
Cancer Med; 2023 May; 12(10):11795-11805. PubMed ID: 36951508
[TBL] [Abstract][Full Text] [Related]
6. The economic burden of skeletal-related events among elderly men with metastatic prostate cancer.
Jayasekera J; Onukwugha E; Bikov K; Mullins CD; Seal B; Hussain A
Pharmacoeconomics; 2014 Feb; 32(2):173-91. PubMed ID: 24435407
[TBL] [Abstract][Full Text] [Related]
7. Total Medicare Costs Associated With Diagnosis and Treatment of Prostate Cancer in Elderly Men.
Trogdon JG; Falchook AD; Basak R; Carpenter WR; Chen RC
JAMA Oncol; 2019 Jan; 5(1):60-66. PubMed ID: 30242397
[TBL] [Abstract][Full Text] [Related]
8. Resource Use in the Last Year of Life Among Patients Who Died With Versus of Prostate Cancer.
Dinan MA; Li Y; Zhang Y; Stewart SB; Curtis LH; George DJ; Reed SD
Clin Genitourin Cancer; 2016 Feb; 14(1):28-37.e2. PubMed ID: 26382223
[TBL] [Abstract][Full Text] [Related]
9. Commentary on "the burden of depression in prostate cancer." Jayadevappa R, Malkowicz SB, Chhatre S, Johnson JC, Gallo JJ, Department of Medicine, University of Pennsylvania School of Medicine, Philadelphia, PA.: Psychooncology 2012;21(12):1338-45. [Epub 2011 Aug 12]. doi: 10.1002/pon.2032.
Hollenbeck BK
Urol Oncol; 2014 Oct; 32(7):1089-90. PubMed ID: 25443144
[TBL] [Abstract][Full Text] [Related]
10. Prostate Cancer Outcomes Following Solid-Organ Transplantation: A SEER-Medicare Analysis.
Liauw SL; Ham SA; Das LC; Rudra S; Packiam VT; Koshy M; Weichselbaum RR; Becker YT; Bodzin AS; Eggener SE
J Natl Cancer Inst; 2020 Aug; 112(8):847-854. PubMed ID: 31728517
[TBL] [Abstract][Full Text] [Related]
11. Short-term androgen suppression and radiotherapy versus intermediate-term androgen suppression and radiotherapy, with or without zoledronic acid, in men with locally advanced prostate cancer (TROG 03.04 RADAR): 10-year results from a randomised, phase 3, factorial trial.
Denham JW; Joseph D; Lamb DS; Spry NA; Duchesne G; Matthews J; Atkinson C; Tai KH; Christie D; Kenny L; Turner S; Gogna NK; Diamond T; Delahunt B; Oldmeadow C; Attia J; Steigler A
Lancet Oncol; 2019 Feb; 20(2):267-281. PubMed ID: 30579763
[TBL] [Abstract][Full Text] [Related]
12. The Clinical and Economic Impacts of Skeletal-Related Events Among Medicare Enrollees With Prostate Cancer Metastatic to Bone.
McDougall JA; Bansal A; Goulart BH; McCune JS; Karnopp A; Fedorenko C; Greenlee S; Valderrama A; Sullivan SD; Ramsey SD
Oncologist; 2016 Mar; 21(3):320-6. PubMed ID: 26865591
[TBL] [Abstract][Full Text] [Related]
13. Survival following primary androgen deprivation therapy among men with localized prostate cancer.
Lu-Yao GL; Albertsen PC; Moore DF; Shih W; Lin Y; DiPaola RS; Yao SL
JAMA; 2008 Jul; 300(2):173-81. PubMed ID: 18612114
[TBL] [Abstract][Full Text] [Related]
14. Fifteen-year survival outcomes following primary androgen-deprivation therapy for localized prostate cancer.
Lu-Yao GL; Albertsen PC; Moore DF; Shih W; Lin Y; DiPaola RS; Yao SL
JAMA Intern Med; 2014 Sep; 174(9):1460-7. PubMed ID: 25023796
[TBL] [Abstract][Full Text] [Related]
15. Racial differences in patterns of treatment among men diagnosed with de novo advanced prostate cancer: A SEER-Medicare investigation.
Beebe-Dimmer JL; Ruterbusch JJ; Cooney KA; Bolton A; Schwartz K; Schwartz AG; Heath E
Cancer Med; 2019 Jun; 8(6):3325-3335. PubMed ID: 31094098
[TBL] [Abstract][Full Text] [Related]
16. Comorbidities and the risk of late-stage prostate cancer.
Fleming ST; McDavid K; Pearce K; Pavlov D
ScientificWorldJournal; 2006 Jul; 6():2460-70. PubMed ID: 17619718
[TBL] [Abstract][Full Text] [Related]
17. Direct economic burden of high-risk and metastatic melanoma in the elderly: evidence from the SEER-Medicare linked database.
Davis KL; Mitra D; Kotapati S; Ibrahim R; Wolchok JD
Appl Health Econ Health Policy; 2009; 7(1):31-41. PubMed ID: 19558193
[TBL] [Abstract][Full Text] [Related]
18. Impact of serious mental illness on the treatment and mortality of older patients with locoregional high-grade (nonmetastatic) prostate cancer: retrospective cohort analysis of 49 985 SEER-Medicare patients diagnosed between 2006 and 2013.
Fried DA; Sadeghi-Nejad H; Gu D; Zhou S; He W; Giordano SH; Pentakota SR; Demissie K; Helmer D; Shen C
Cancer Med; 2019 May; 8(5):2612-2622. PubMed ID: 30945473
[TBL] [Abstract][Full Text] [Related]
19. Physician visits and the timing of skeletal-related events among men newly diagnosed with metastatic prostate cancer: A cohort analysis.
Onukwugha E; Albarmawi H; Sun K; Mullins CD; Aly A; Hussain A
Urol Oncol; 2018 Jul; 36(7):340.e23-340.e31. PubMed ID: 29724482
[TBL] [Abstract][Full Text] [Related]
20. Association between Types of Chronic Conditions and Cancer Stage at Diagnosis among Elderly Medicare Beneficiaries with Prostate Cancer.
Raval AD; Madhavan S; Mattes MD; Sambamoorthi U
Popul Health Manag; 2016 Dec; 19(6):445-453. PubMed ID: 27031642
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
